See more : Similarweb Ltd. (SMWB) Income Statement Analysis – Financial Results
Complete financial analysis of NextCure, Inc. (NXTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NextCure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zions Bancorporation, National Association (0M3L.L) Income Statement Analysis – Financial Results
- KNH Enterprise Co., Ltd. (9919.TW) Income Statement Analysis – Financial Results
- Kohsoku Corporation (7504.T) Income Statement Analysis – Financial Results
- Golden Ocean Group Limited (GOGL.OL) Income Statement Analysis – Financial Results
- Marblegate Acquisition Corp. (GATEW) Income Statement Analysis – Financial Results
NextCure, Inc. (NXTC)
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 22.38M | 6.35M | 0.00 | 0.00 |
| Cost of Revenue | 3.68M | 4.48M | 4.30M | 46.55K | 34.22K | 1.68M | 582.00K |
| Gross Profit | -3.68M | -4.48M | -4.30M | 22.33M | 6.31M | -1.68M | -582.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.79% | 99.46% | 0.00% | 0.00% |
| Research & Development | 47.93M | 54.20M | 50.19M | 46.55M | 34.22M | 19.79M | 12.95M |
| General & Administrative | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Other Expenses | 0.00 | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Operating Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Cost & Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Interest Income | 0.00 | 1.17M | 1.32K | 4.55K | 3.75K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 77.00K | 183.00K | 209.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.68M | 4.48M | 4.30M | 3.41M | 2.69M | 1.68M | 582.00K |
| EBITDA | -59.04M | -70.25M | -65.01M | -37.81M | -34.79M | -21.10M | -14.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -548.20% | 0.00% | 0.00% |
| Operating Income | -67.64M | -75.91M | -70.77M | -41.23M | -37.48M | -23.20M | -15.55M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -590.55% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.91M | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Income Before Tax | -62.72M | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M | -15.47M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -163.57% | -531.54% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.30M | 6.96M | -3.41M | 2.52M | 397.00K | 0.00 |
| Net Income | -62.72M | -69.43M | -69.39M | -33.19M | -33.74M | -22.80M | -15.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -148.32% | -531.54% | 0.00% | 0.00% |
| EPS | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| EPS Diluted | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| Weighted Avg Shares Out | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
| Weighted Avg Shares Out (Dil) | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
NextCure to Present at the JMP Securities Life Sciences Conference
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
NextCure to Present at SVB Securities Global Biopharma Conference
NextCure to Present at Upcoming Investor Conferences
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
NextCure to Present at the JMP Securities Life Sciences Conference
Source: https://incomestatements.info
Category: Stock Reports